Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 14/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11619004 | 0.84 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL17540778 | 0.81 | CNR1 (0.49) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL12244367 | 0.79 | CCNB2 (0.75) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL17548540 | 0.76 | CNR1 (0.40) | CCNB2CDK1CCNB1CCNB3CNR1 | |
| SCHEMBL10933044 | 0.76 | CCNB2 (0.61) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL11797871 | 0.76 | CCNB2 (0.57) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL7645847 | 0.76 | CCNB2 (0.57) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL11656880 | 0.74 | CCNB2 (0.55) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL21228922 | 0.72 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL17540738 | 0.72 | CNR1 (0.74) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2019-08-13 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CCNB2 2581/4885CDK1 950/4885CCNB1 2120/4885 |
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | CNR1, CNR2, GPR18 | CCNB2 2581/4885CDK1 950/4885CCNB1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.